Hello, everyone, and how are you this morning? We are doing just fine, thank you, despite another round of wintry temperatures enveloping the Pharmalot campus. Of course, we combat the chill by brewing a few cups of stimulation. Today, we are toggling between chocolate cherry decadence and butter pecan. Feel free to offer suggestions. Meanwhile, we have assembled the usual menu of tidbits to help you on your busy journey. We hope it goes well and you have a productive day. And, as always, do keep in touch …

AbbVie (ABBV) halted enrollment for a late-stage trial of a drug called Rova-T as a second-line therapy for advanced small-cell lung cancer after the medicine demonstrated shorter overall survival than a control arm, Reuters tells us. AbbVie acquired Rova-T through its $5.8 billion acquisition of Stemcentrx in 2016, as it aimed to enter the broad and lucrative arena of solid tumors and lessen dependence on its Humira arthritis treatment. But in March, AbbVie said it would not seek accelerated approval for the drug, a setback to its efforts to build its cancer drug pipeline.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!